

--This application is a continuation of Application No. 09/650,684, filed on August 30, 2000; which is a divisional of Application No. 09/390,280, filed on September 3, 1999; which is a continuation-in-part of Application No. 09/168,885, filed on October 9, 1998. The disclosure of each of the above applications is incorporated herein by reference in their entirety--.

**IN THE CLAIMS:**

Claims 1-59 are pending in this application prior to the amendments.

Claims 1-59 are being canceled without prejudice or disclaimer. New claims 60-82 are being added.

60. (New) An immunoassay kit for measuring the amount of a cyclosporine related compound in a sample, said cyclosporine related compound selected from the group consisting of CSA, a CSA metabolite, and a CSA derivative, said kit comprising an antibody selected from the group consisting of :
- CSA-2G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4170;
- AM1-7F5 produced by the hydridoma cell line deposited with the ATCC as PTA-4142;
- AM1-3B1 produced by the hydridoma cell line deposited with the ATCC as PTA-4154;
- AM1-2E10 produced by the hydridoma cell line deposited with the ATCC as PTA-4141;
- AM9-1-3C1 produced by the hydridoma cell line deposited with the ATCC as PTA-4155;
- AM19-1-5D2 produced by the hydridoma cell line deposited with the ATCC as PTA-4163;
- AM19-1-5B3 produced by the hydridoma cell line deposited with the ATCC as PTA-4147;
- AM19-9-5A6 produced by the hydridoma cell line deposited with the ATCC as PTA-4150;

AM9-1-6D4 produced by the hydridoma cell line deposited with the ATCC as PTA-4157;

AM9-1-7D2 produced by the hydridoma cell line deposited with the ATCC as PTA-4144;

AM9-9-11G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4158;

AM9-9-6C3 produced by the hydridoma cell line deposited with the ATCC as PTA-4146;

AM19-1-7E12 produced by the hydridoma cell line deposited with the ATCC as PTA-4161;

AM9-1-2A11 produced by the hydridoma cell line deposited with the ATCC as PTA-4143;

AM19-9-1E11 produced by the hydridoma cell line deposited with the ATCC as PTA-4149;

AM19-9-1D8 produced by the hydridoma cell line deposited with the ATCC as PTA-4148;

AM19-9-2G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4160;

AM9-9-11H11 produced by the hydridoma cell line deposited with the ATCC as PTA-4159;

AM9-9-4F5 produced by the hydridoma cell line deposited with the ATCC as PTA-4145; and

AM9-1-4D6 produced by the hydridoma cell line deposited with the ATCC as PTA-4156.

61. (New) The kit of claim 60 wherein said antibody is selective for said CSA metabolite and said metabolite is selected from the group consisting of AM1, AM1c, AM9, and AM19.
62. (New) The kit of claim 60 wherein said antibody is selective for CSA.

63. (New) The kit of claim 60 wherein said antibody is selective for said cyclosporine derivative and said derivative is modified at the amino acid 1 residue.
64. (New) The kit of claim 60 wherein said antibody is selected from the group consisting of AM1-2E10, AM19-9-5A6, and AM9-1-6D4.
65. (New) The kit of claim 60 wherein said antibody is selected from the group consisting of CSA-2G9, AM1-2E10, AM1-7F5, and AM19-1-7E12.
66. (New) The kit of claim 60 wherein said antibody is CSA-2G9.
67. (New) The kit of claim 60 wherein said antibody is selected from the group consisting of AM9-1-7D2, AM9-9-6C3 and AM9-9-11G9.
68. (New) An immunoassay kit for measuring the amount of a cyclosporine related compound in a sample, said cyclosporine related compound selected from the group consisting of CSA, a CSA metabolite, and a CSA derivative, said kit comprising a first antibody and a second antibody, said first antibody and said second antibody independently selected from the group consisting of :  
CSA-2G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4170;  
AM1-7F5 produced by the hydridoma cell line deposited with the ATCC as PTA-4142;  
AM1-3B1 produced by the hydridoma cell line deposited with the ATCC as PTA-4154;  
AM1-2E10 produced by the hydridoma cell line deposited with the ATCC as PTA-4141;  
AM9-1-3C1 produced by the hydridoma cell line deposited with the ATCC as PTA-4155;  
AM19-1-5D2 produced by the hydridoma cell line deposited with the ATCC as PTA-4163;

AM19-1-5B3 produced by the hydridoma cell line deposited with the ATCC as PTA-4147;

AM19-9-5A6 produced by the hydridoma cell line deposited with the ATCC as PTA-4150;

AM9-1-6D4 produced by the hydridoma cell line deposited with the ATCC as PTA-4157;

AM9-1-7D2 produced by the hydridoma cell line deposited with the ATCC as PTA-4144;

AM9-9-11G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4158;

AM9-9-6C3 produced by the hydridoma cell line deposited with the ATCC as PTA-4146;

AM19-1-7E12 produced by the hydridoma cell line deposited with the ATCC as PTA-4161;

AM9-1-2A11 produced by the hydridoma cell line deposited with the ATCC as PTA-4143;

AM19-9-1E11 produced by the hydridoma cell line deposited with the ATCC as PTA-4149;

AM19-9-1D8 produced by the hydridoma cell line deposited with the ATCC as PTA-4148;

AM19-9-2G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4160;

AM9-9-11H11 produced by the hydridoma cell line deposited with the ATCC as PTA-4159;

AM9-9-4F5 produced by the hydridoma cell line deposited with the ATCC as PTA-4145; and

AM9-1-4D6 produced by the hydridoma cell line deposited with the ATCC as PTA-4156.

69. (New) The kit of claim 68 wherein said first antibody is specific for at least one CSA metabolite selected from the group consisting of AM1, AM1c, AM9, and AM19.

70. (New) The kit of claim 69 wherein said second antibody is selective for CSA.
71. (New) The kit of claim 68 wherein said first antibody is purified.
72. (New) The kit of claim 71 wherein said first antibody is selected from the group consisting of:
- AM1-2E10 produced by the hydridoma cell line deposited with the ATCC as PTA-4141;
  - AM19-9-5A6 produced by the hydridoma cell line deposited with the ATCC as PTA-4150;
  - AM9-1-6D4 produced by the hydridoma cell line deposited with the ATCC as PTA-4157;
  - AM9-1-7D2 produced by the hydridoma cell line deposited with the ATCC as PTA-4144;
  - AM9-9-11G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4158;
  - AM9-9-6C3 produced by the hydridoma cell line deposited with the ATCC as PTA-4146;
  - AM19-1-7E12 produced by the hydridoma cell line deposited with the ATCC as PTA-4161;
  - AM9-1-2A11 produced by the hydridoma cell line deposited with the ATCC as PTA-4143;
  - AM19-9-1E11 produced by the hydridoma cell line deposited with the ATCC as PTA-4149;
  - AM19-9-1D8 produced by the hydridoma cell line deposited with the ATCC as PTA-4148;
  - AM19-9-2G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4160; and
  - AM9-1-4D6 produced by the hydridoma cell line deposited with the ATCC as PTA-4156.

73. (New) The kit of claim 71 wherein said second antibody is selected from the group consisting of CSA-2G9, AM1-2E10, AM1-7F5, and AM19-1-7E12.
74. (New) The kit of claim 68 wherein said compound is modified at the amino acid 1 residue. and said second antibody is selected from the group consisting of CSA-2G9, AM1-2E10, AM1-7F5, and AM19-1-7E1
75. (New) The kit of claim 68 wherein said compound is CSG and said second antibody is CSA-2G9.
76. (New) The kit of claim 72 wherein said second antibody is purified and is selected from the group consisting of:  
AM1-2E10 produced by the hydridoma cell line deposited with the ATCC as PTA-4141;  
AM19-9-5A6 produced by the hydridoma cell line deposited with the ATCC as PTA-4150;  
AM9-1-6D4 produced by the hydridoma cell line deposited with the ATCC as PTA-4157;  
AM19-1-7E12 produced by the hydridoma cell line deposited with the ATCC as PTA-4161;  
AM9-1-2A11 produced by the hydridoma cell line deposited with the ATCC as PTA-4143;  
AM19-9-1E11 produced by the hydridoma cell line deposited with the ATCC as PTA- 4149;  
AM19-9-1D8 produced by the hydridoma cell line deposited with the ATCC as PTA-4148;  
AM19-9-2G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4160; and  
AM9-1-4D6 produced by the hydridoma cell line deposited with the ATCC as PTA-4156.

77. (New) The kit of claim 76 further comprising a third antibody, said third antibody selected from the group consisting of CSA-2G9, AM1-2E10, and AM1-7F5.
78. (New) The kit of claim 68 further comprising a third antibody, said third antibody selected from the group consisting of CSA-2G9, AM1-2E10, and AM1-7F5.
79. (New) The kit for measuring AM9 in a biological sample, said kit comprising at least one antibody selected from the group consisting of AM9-1-7D2, AM9-911G9, and AM9-9-6C3 and at least one antibody selected from the group consisting of CSA-2G9, AM1-2E10, AM19-7E12, and AM1-7F5.
80. (New) The kit of claim 68 wherein said sample is a biological sample.
81. (New) The kit of claim 68 wherein said first antibody binds to one face of the CSA molecule and said second antibody binds to the other face of the CSA molecule.
82. (New) A kit for quantifying CSA in an automated TDM, said kit comprising an antibody selected from the group consisting of :  
CSA-2G9 produced by the hydridoma cell line deposited with the ATCC as PTA-4170;  
AM1-7F5 produced by the hydridoma cell line deposited with the ATCC as PTA-4142;  
AM1-3B1 produced by the hydridoma cell line deposited with the ATCC as PTA-4154;  
AM1-2E10 produced by the hydridoma cell line deposited with the ATCC as PTA-4141;  
AM9-1-3C1 produced by the hydridoma cell line deposited with the ATCC as PTA-4155;  
AM19-1-5D2 produced by the hydridoma cell line deposited with the ATCC as PTA-4163;